Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
NCT ID: NCT00047762
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
INTERVENTIONAL
2002-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erlotinib (aka Tarceva or OSI-774)
Bevacizumab (aka Avastin or Rhu MAb VEGF)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
* Histologically confirmed metastatic colorectal adenocarcinoma of the colon or rectum
Resected or biopsied primary tumors or metastatic site will serve as the basis for histologic confirmation.
* Measurable disease (defined as at least one dimension \>2 cm \[\>1 cm on spiral CT scans\])
* ECOG performance status of 0 or 1
* Life expectancy \>3 months
* Use of an effective means of contraception in men and in women of childbearing potential
* Ability to comply with study and follow-up procedures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indiana University Cancer Pavilion
Indianapolis, Indiana, United States
Johns Hopkins Oncology Center
Baltimore, Maryland, United States
Mary Crowley Medical Research Center
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OSI2520g
Identifier Type: -
Identifier Source: org_study_id